ArticleInternational journal of molecular sciences2020
Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Prognostic value of nectin-4 in human cancers: A meta-analysis.Frontiers in oncology · 2023Pooled it
- Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma.Translational andrology and urology · 2026Article
- Nectin-4 expression in clear cell renal cell carcinoma.Scientific reports · 2026Article
- Nectin-4 expression in upper and lower tract urothelial carcinoma: correlation with early-stage disease and prognostic relevance.Virchows Archiv : an international journal of pathology · 2026Article
- Treatment strategies for locally advanced and metastatic urothelial carcinoma based on molecular profiles: A Review.Histology and histopathology · 2026Review
- Trimbody with rigid AI-designed scaffolds enables atomic-resolution cryo-EM structure determination of small proteins.Nature communications · 2026Article
- Cavitation of Pulmonary Metastases During Enfortumab Vedotin for Metastatic Ureteral Urothelial Carcinoma.IJU case reports · 2026Article
- Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis.European urology open science · 2025Review
- Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer.Scientific reports · 2025Article
- Article
- Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.Translational andrology and urology · 2025Article
- Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.BJU international · 2025Article
- Nectin-4 expression patterns and therapeutics in oncology.Cancer letters · 2025Review
- Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry - what do we know?Histology and histopathology · 2025Review
- Nectin4-targeted molecular imaging in solid tumors: Current status and future perspectives.View (Beijing, China) · 2025Article
- Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2.Current issues in molecular biology · 2025Article
- Treatment-related skin reactions in enfortumab vedotin as a surrogate marker of survival and treatment response.International journal of clinical oncology · 2025Article
- Impact of Membranous Nectin-4 on Outcomes of Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma.Cancers · 2025Article
- Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances.Exploration of targeted anti-tumor therapy · 2025Review
- First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials.Therapeutic advances in medical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enfortumab vedotin is a novel antibody-drug conjugate targeting Nectin-4, which is highly expressed in urothelial carcinoma. However, the expression status of Nectin-4 in upper tract urothelial carcinoma (UTUC) remains unclear. The relationship between Nectin-4 and Programmed Death Ligand 1 (PD-L1) in UTUC is also ambiguous. We performed immunohistochemical analysis of 99 UTUC tissue microarray to assess the expression of Nectin-4 and PD-L1 in UTUC. Nectin-4-positivity was detected in 65 (65.7%) samples, and PD-L1 was detected in 24 (24.2%) samples. There was no correlation between the expression of Nectin-4 and PD-L1. Patients with strong Nectin-4-expressing tumors had a significantly higher risk of progression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.